We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

UK drugmaker says Emma Walmsley is underpaid compared with global competitors as it abandons diversity targets ...

Dominic Rose, an analyst at Intron Health, also sees shareholder activism as a possibility given GSK’s share-price ...

British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...

The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,608, up by ₹275.75, or 11.82%, on the BSE. Brokerage firms, ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the BSE.